Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases.
$2.42+5.68%
报价 2026-11-13
市值
$138.3M
EV
$198.7M
PE (TTM)
3.3x
预期 PE (FY2026)
–
52 周区间距高点 -67.6%
$2.29$7.46
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ABEOAbeona Therapeutics Inc. | $138.3M | +5.7% | +1241.7% | 26.3% | 3.3x | – | – | |
| ASMBAssembly Biosciences, Inc. | $432.5M | +4.7% | +70.9% | 72.9% | 54.5x | – | – | |
| PBYIPuma Biotechnology, Inc. | $401.7M | -3.8% | +2.0% | 74.5% | 10.1x | 5.4x | 27.8x | |
| SGMTSagimet Biosciences Inc. | $333M | -6.5% | -90.0% | 0% | – | – | – | |
| ARCTArcturus Therapeutics Holdings Inc. | $241M | -0.9% | -81.3% | 24% | – | – | – | |
| ELDNEledon Pharmaceuticals, Inc. | $178.6M | -10.6% | -100.0% | 0% | – | – | – | |
| HUMAHumacyte, Inc. | $155.1M | -6.2% | +174.1% | -533% | – | – | – | |
| FHTXFoghorn Therapeutics Inc. | $124.1M | +1.0% | -18.9% | 99.1% | 29.9x | 8.0x | – | |
| VYGRVoyager Therapeutics, Inc. | $107.7M | +1.8% | +31.0% | 89.9% | – | – | – | |
| 同行中位数 | – | – | -8.4% | 48.5% | 29.9x | 6.7x | 27.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。